C
Champions Oncology, Inc. (CSBR)
5.74
0.00 (0.00%)
Get all premium features to the best stock analysis tool
5.74
0.00 (0.00%)
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 0.98 | 6.05 | 6.0 | |
| Quick ratio | 0.98 | 5.63 | 6.0 | |
| Debt to Equity | 1.17 | 0.30 | 6.0 | |
| Debt to Assets | 0.18 | 1.04 | 8.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 5.4 | |||
| METRIC | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 49M | 54M | 50M | 57M | 58M |
| Gross Profit | 25M | 24M | 21M | 27M | 25M |
| Operating Income | 607K | -4M | -7M | 5M | -2M |
| Net Income | 548K | -5M | -7M | 5M | -2M |
| EBITDA | 3M | -1M | -5M | 6M | -773K |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 4.3 | 28.57 | 7.0 |
| Next quarter | 7.5 | -150 | 3.0 |
| Current year | 2.78 | -76.47 | 2.5 |
| Next year | 11.51 | -16.67 | 4.0 |
| Weighted average score | 4.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 10.14 | -204.09 | -133.32 | 30.4 | 4.8 |
| Y/Y | -2.81 | -106.2 | -105.55 | -407.13 | 1.0 |
| 3y average | 5.45 | -315.09 | -75.55 | -202.26 | 2.0 |
| 5y average | 12.75 | -155.31 | -5.66 | -249.65 | 2.8 |
| Weighted average score | 2.7 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $7.1M significantly exceed its total debt $5.0M, ensuring strong financial flexibility
Total current assets $20.2M are just enough to cover Total current liabilities $20.7M, indicating tight liquidity
Debt-to-equity ratio (1.1) is near the industry average, reflecting balanced leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$1.4M limits the company's ability to reinvest or pay down debt